Skip to main navigation
Coeptis Therapeutics Homepage
search
Menu
  • News
  • Search
Press enter to begin your search
Close Search
Our Science

Overview

NOVEL STEM CELL EXPANSION TECHNOLOGY

UNMODIFIED IMMUNE EFFECTOR CELL PROGRAM

SNAP-CAR

GEAR-NK (CD38)

About
Investors & Media

Overview

News & Events

Corporate Governance

SEC Filings

Stock Information

IR Resources

Join Our Team
Contact

Media Coverage

New & Events
  • News Releases
  • Events & Presentations
  • Media Coverage
Stem-Cell Derived Therapies: From Source To Site

Cell & Gene

...
April 16, 2024
Coeptis CEO Dave Mehalick on NASDAQ listing and entering the Cancer Treatment Race

Investor News

...
December 28, 2023
SNAP, CAR-M and BiTE: New immunotherapy approaches previewed at SITC

FierceBiotech

...
November 6, 2023
Local pharma firm widens technology deal with the University of Pittsburgh

Pittsburgh Business Times

...
October 11, 2023
Universalizing Allogeneic Cell Therapies With Cord-Blood-Derived Stem Cells

Cell & Gene

...
September 26, 2023
Coeptis announces Deverra Therapeutics gets two Life Science Start-Up and Development Awards from Washington's Cancer Research Endowment

PharmaBiz

...
September 12, 2023
Coeptis appoints Colleen Delaney as chief scientific and medical officer

Pittsburgh Business Times

...
September 4, 2023
Coeptis licenses Deverra Therapeutics’ clinical stage assets

Pharmaceutical Technology

...
August 18, 2023
Coeptis Therapeutics becomes clinical-stage company following license acquisition from Deverra Therapeutics

Pittsburgh Business Times

...
August 17, 2023
Considerations For Licensing Platforms From Universities

Cell & Gene

...
June 16, 2023
  • Current page 1
  • Page 2
  • Next page ›
  • Last page »
Coeptis Therapeutics Holdings, Inc. Footer Logo

Coeptis Therapeutics Holdings, Inc.

Corporate Headquarters
105 Bradford Road, Suite 420
Wexford, PA 15090
+1 (724) 934-6467
info@coeptistx.com

Site - Footer Menu 1

Our Science
About
Investors & Media

Site - Footer Menu 2

Join Our Team
Contact
News

Site - Footer Social Navigation

linkedin
twitter
mail

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission. The statements that are not historical facts contained in releases or in our posted events and presentations are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings. Coeptis Therapeutics Holdings, Inc. does not undertake any obligation to update forward-looking statements after the date of such releases except to the extent required under applicable federal and state securities laws. This website contains links to websites maintained by other companies. Coeptis Therapeutics is providing these links to readers only as a convenience. The inclusion of any link does not imply that Coeptis Therapeutics endorses any third-party website or third-party company or product. Coeptis Therapeutics does not have any control over the content of such third-party websites and assumes no responsibility whatsoever for the functionality of such websites or for the accuracy of any information presented at such other websites.

Site - Footer Copyright Navigations

Privacy Policy
Terms of Service
DMCA Policy

© Copyright Coeptis Therapeutics Holdings, Inc. 2026

Close Menu
  • Our Science
    • Overview
    • NOVEL STEM CELL EXPANSION TECHNOLOGY
    • UNMODIFIED IMMUNE EFFECTOR CELL PROGRAM
    • SNAP-CAR
    • GEAR-NK (CD38)
  • About
  • Investors & Media
    • Overview
    • News & Events
    • Corporate Governance
    • SEC Filings
    • Stock Information
    • IR Resources
  • Join Our Team
  • Contact